Compensatory Interventions for Cognitive Impairments in Psychosis: A Systematic Review and Meta-Analysis.

environmental modification errorless learning external strategies functional outcome internal self-management schizophrenia severe mental illness

Journal

Schizophrenia bulletin
ISSN: 1745-1701
Titre abrégé: Schizophr Bull
Pays: United States
ID NLM: 0236760

Informations de publication

Date de publication:
08 07 2020
Historique:
pubmed: 14 2 2020
medline: 18 5 2021
entrez: 14 2 2020
Statut: ppublish

Résumé

Cognitive compensatory interventions aim to alleviate psychosocial disability by targeting functioning directly using aids and strategies, thereby minimizing the impact of cognitive impairment. The aim was to conduct a systematic review and meta-analysis of cognitive compensatory interventions for psychosis by examining the effects on functioning and symptoms, and exploring whether intervention factors, study design, and age influenced effect sizes. Electronic databases (Ovid Medline, PsychINFO) were searched up to October 2018. Records obtained through electronic and manual searches were screened independently by two reviewers according to selection criteria. Data were extracted to calculate estimated effects (Hedge's g) of treatment on functioning and symptoms at post-intervention and follow-up. Study quality was assessed using Cochrane Collaboration's risk of bias tool. Twenty-six studies, from 25 independent randomized controlled trials (RCTs) were included in the meta-analysis (1654 participants, mean age = 38.9 years, 64% male). Meta-analysis revealed a medium effect of compensatory interventions on functioning compared to control conditions (Hedge's g = 0.46, 95% CI = 0.33, 0.60, P < .001), with evidence of relative durability at follow-up (Hedge's g = 0.36, 95% CI = 0.19, 0.54, P < .001). Analysis also revealed small significant effects of cognitive compensatory treatment on negative, positive, and general psychiatric symptoms, but not depressive symptoms. Estimated effects did not significantly vary according to treatment factors (ie, compensatory approach, dosage), delivery method (ie, individual/group), age, or risk of bias. Longer treatment length was associated with larger effect sizes for functioning outcomes. No evidence of publication bias was identified. Cognitive compensatory interventions are associated with robust, durable improvements in functioning in people with psychotic illnesses.

Identifiants

pubmed: 32052837
pii: 5735262
doi: 10.1093/schbul/sbz134
pmc: PMC7345816
doi:

Types de publication

Journal Article Meta-Analysis Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

869-883

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Références

Am J Psychiatr Rehabil. 2008 Apr;11(2):144-163
pubmed: 19198664
Schizophr Res. 2019 Jan;203:12-16
pubmed: 28919130
Schizophr Bull. 2013 Sep;39(5):999-1007
pubmed: 23086987
Psychiatr Rehabil J. 2013 Sep;36(3):133-45
pubmed: 24059629
Neuropsychiatr Dis Treat. 2006 Dec;2(4):531-6
pubmed: 19412501
Implement Sci. 2011 Apr 23;6:42
pubmed: 21513547
Aust N Z J Psychiatry. 2016 May;50(5):497
pubmed: 26607301
Schizophr Bull. 2008 May;34(3):483-93
pubmed: 17932089
Psychiatry Res. 2017 Jan;247:21-27
pubmed: 27863314
Arch Gen Psychiatry. 2012 Feb;69(2):121-7
pubmed: 21969420
Curr Psychiatry Rep. 2003 Aug;5(4):303-10
pubmed: 12857534
J Clin Psychiatry. 2012 Sep;73(9):1212-9
pubmed: 22939029
Schizophr Bull. 2015 May;41(3):597-603
pubmed: 25193976
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Schizophr Res Treatment. 2012;2012:815315
pubmed: 22966447
J Clin Exp Neuropsychol. 2010 Nov;32(9):1017-27
pubmed: 20446142
Schizophr Bull. 2009 Jul;35(4):807-15
pubmed: 18326529
Schizophr Bull. 2009 Mar;35(2):347-61
pubmed: 19176470
Schizophr Bull. 2010 Sep;36(5):957-65
pubmed: 20634277
J Clin Exp Neuropsychol. 2006 Jan;28(1):101-10
pubmed: 16448979
Psychol Med. 2019 Jul;49(9):1414-1425
pubmed: 30696500
Am J Psychiatry. 2007 Mar;164(3):437-41
pubmed: 17329468
Schizophr Res. 2009 Sep;113(2-3):252-8
pubmed: 19524409
J Head Trauma Rehabil. 2014 Jul-Aug;29(4):369-86
pubmed: 24984098
Psychiatr Rehabil J. 2017 Mar;40(1):61-69
pubmed: 28368180
Schizophr Bull. 2009 Mar;35(2):319-35
pubmed: 19269925
Psychiatr Serv. 2006 Oct;57(10):1421-9
pubmed: 17035559
Psychol Med. 2003 Apr;33(3):433-42
pubmed: 12701664
Schizophr Bull. 1999;25(2):257-74
pubmed: 10416730
Br J Clin Psychol. 2010 Jun;49(Pt 2):259-74
pubmed: 19735607
Schizophr Bull. 2005 Oct;31(4):898-909
pubmed: 16079391
Schizophr Bull. 2011 Sep;37 Suppl 2:S55-62
pubmed: 21860048
Psychiatr Rehabil J. 2018 Jun;41(2):109-117
pubmed: 27547853
Schizophr Res. 2016 Aug;175(1-3):48-56
pubmed: 27209526
Schizophr Res. 2015 Mar;162(1-3):108-11
pubmed: 25631454
Schizophr Bull. 2018 Jan 13;44(1):38-45
pubmed: 28981901
Schizophr Res. 2009 Oct;114(1-3):71-8
pubmed: 19643579
Schizophr Bull. 2009 Jul;35(4):798-806
pubmed: 18308717
Schizophr Res. 2019 Jan;203:41-48
pubmed: 28823720
Schizophr Res. 2004 Dec 1;71(2-3):339-48
pubmed: 15474904
Schizophr Res. 2015 Oct;168(1-2):213-22
pubmed: 26305063
Neurosci Biobehav Rev. 2011 Jan;35(3):573-88
pubmed: 20620163
Psychiatr Serv. 1996 Apr;47(4):415-7
pubmed: 8689375
Schizophr Bull. 2003;29(2):359-82
pubmed: 14552510
Schizophr Bull. 2005 Jan;31(1):55-66
pubmed: 15888425
Neuropsychol Rev. 2009 Sep;19(3):353-64
pubmed: 19444614
Schizophr Res. 2008 Jul;102(1-3):312-9
pubmed: 18374542
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
Am J Psychiatry. 2002 Nov;159(11):1921-6
pubmed: 12411229
Schizophr Res. 2015 Feb;161(2-3):399-402
pubmed: 25534069
Am J Psychiatry. 2005 Mar;162(3):513-9
pubmed: 15741468
Work. 2017;56(4):581-589
pubmed: 28339416
Schizophr Bull. 2002;28(2):283-92
pubmed: 12693434
Am J Psychiatry. 2000 Aug;157(8):1317-23
pubmed: 10910797
Am J Psychiatry. 2011 May;168(5):472-85
pubmed: 21406461
Acta Psychiatr Scand. 2014 Oct;130(4):300-10
pubmed: 24833315
Neuropsychology. 2009 Jul;23(4):445-59
pubmed: 19586209
Am J Psychiatry. 2007 Dec;164(12):1791-802
pubmed: 18056233
Am J Psychiatry. 2015 Sep 1;172(9):852-61
pubmed: 25998278
Epidemiol Psychiatr Sci. 2017 Aug;26(4):364-368
pubmed: 27790968
Psychol Med. 1999 Jan;29(1):105-12
pubmed: 10077298

Auteurs

Kelly Allott (K)

Orygen, Parkville, Australia.
Centre for Youth Mental Health, The University of Melbourne, Parkville, Australia.

Kristi van-der-El (K)

Orygen, Parkville, Australia.
Centre for Youth Mental Health, The University of Melbourne, Parkville, Australia.

Shayden Bryce (S)

Orygen, Parkville, Australia.
Centre for Youth Mental Health, The University of Melbourne, Parkville, Australia.

Emma M Parrish (EM)

San Diego State University/University of California San Diego Joint Doctoral Program in Clinical Psychology, San Diego State University, San Diego, CA.

Susan R McGurk (SR)

Department of Occupational Therapy, Center for Psychiatric Rehabilitation, Boston University, Boston, MA.

Sarah Hetrick (S)

Orygen, Parkville, Australia.
Centre for Youth Mental Health, The University of Melbourne, Parkville, Australia.
Department of Psychological Medicine, University of Auckland, Auckland, New Zealand.

Christopher R Bowie (CR)

Department of Psychology, Queen's University, Kingston, Ontario, ON, Canada.

Sean Kidd (S)

Department of Psychiatry, University of Toronto, Toronto, Ontario, ON, Canada.

Matthew Hamilton (M)

Orygen, Parkville, Australia.
Centre for Youth Mental Health, The University of Melbourne, Parkville, Australia.

Eoin Killackey (E)

Orygen, Parkville, Australia.
Centre for Youth Mental Health, The University of Melbourne, Parkville, Australia.

Dawn Velligan (D)

Department of Psychiatry, University of Texas Health Science Centre, San Antonio, TX.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH